CXCL13 and neoplasm: In summary, our findings suggest that IFN-I signature enrichment is a distinguishing feature of tumor-infiltrating, tumor-reactive Ki67+ CXCL13+CD4+ T cells that license cDC1s for the induction of antitumor CTL activity in the TME, which potentially leads to a favorable clinical outcome (Fig. 8L).